Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

House Blocks Government Reimbursement For Erectile Dysfunction Drugs

This article was originally published in The Pink Sheet Daily

Executive Summary

The amendment added to the fiscal 2006 HHS spending bill prohibits federal spending on Viagra, Levitra and Cialis but does not mention other products.

You may also be interested in...



HHS Approps Bill Moves To Senate Floor

The Senate's fiscal 2006 HHS appropriations bill will move to the floor after being marked up by the full Appropriations Committee July 14

HHS Approps Bill Moves To Senate Floor

The Senate's fiscal 2006 HHS appropriations bill will move to the floor after being marked up by the full Appropriations Committee July 14

Senate Medicare Part D Appropriations

The Senate Appropriations/Labor, HHS & Education Subcommittee is budgeting $53.6 bil. for the first nine months of the Medicare Part D drug benefit

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS062447

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel